AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Achaogen, Inc.

1 Tower Place
Suite 400
South San Francisco, CA 94080
United States
650-800-3636
http://www.achaogen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees42

Key Executives

NameTitlePayExercisedYear Born
Mr. Blake WiseCEO, Principal Financial Officer, Principal Accounting Officer & Director600.75kN/A1971
Mr. Gary LoebGen. Counsel, Corp. Sec. & Chief Compliance Officer458kN/A1970
Ms. Elizabeth BhattChief Bus. Officer & COON/AN/A1969
Ms. Jeannie LloydsVP of SalesN/AN/AN/A
Ms. Janet DorlingChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Achaogen, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.